AbbVie will present Phase III TEMPLE study results at the 2025 International Headache Congress, showing atogepant’s superior tolerability and efficacy over topiramate for migraine prevention. Atogepant...
AbbVie and Simcere Zaiming announced a licensing option agreement to develop SIM0500, a trispecific antibody targeting multiple myeloma. Currently in Phase I trials, SIM0500 induces strong...
BaseLaunch, a Basel biotech incubator, gains support from AbbVie, joining Roche, Novo Nordisk, Johnson & Johnson, and CSL Behring. Operated by Basel Area Business & Innovation,...